Jun and Fos family protein expression in human breast cancer: Correlation of protein expression and clinicopathological parameters

Objectives: The activator protein-1 (AP-1) is a dimeric transcription factor formed by members of the Jun and Fos protein family. AP-1 plays a role in a variety of physiological functions including cell proliferation and differentiation, although both c-Jun and c-Fos have also been implicated in oncogenic transformation and tumor progression. To further elucidate the role of AP-1 in breast cancer, we have investigated the expression of the AP-1 proteins c-Jun, JunB, JunD, phosphorylated c-Jun, c-Fos, Fral, Fra2 and the tumor supressor protein p53.

Methods: Protein expression was evaluated on a breast cancer tissue microarray with 58 lymph node positive or negative breast cancer specimens, 29 corresponding lymph node metastases, and 11 tissue samples from surrounding tumor-free tissue, each cored as triplicate. Jun and Fos protein family expression was evaluated by immunohistochemistry and was correlated with clinicopathological parameters.

Results: High expression levels were observed for c-Jun, JunD, c-Fos and Fra2, whereas JunB and Fral exhibited lower staining. c-Jun protein expression was correlated to Fral staining (p = 0.007, Kendall's Tau) and Fral was further associated with c-Fos (p < 0.001), JunD (p = 0.001) and Fra2 (p = 0.011) expression. JunD expression correlated with c-Fos (p < 0.001), JunB (p = 0.035) and c-Jun (p = 0.05). Activated c-Jun correlated with c-Fos expression (p = 0.041). JunB was negatively correlated to tumor stage, (p = 0.093, corr coeff. = -0.293, Spearman's correlation) but was significantly increased in nodal negative tumors (p = 0.004, Mann Whitney test). In addition, increased Fral expression showed a trend towards an increased overall survival (p = 0.077, RR = 0.534, Cox regression).

Conclusion: Our results suggest an important role for JunB and Fral in the biological behavior of malignant breast tumors.

AP-I; Jun; Fos; Breast cancer

[1] Angel P., Karin M.:'The role of Jun, Fos and the AP-I complex in cell proliferation and transformation". Biochim. Biophys. Acta, 1991, 1072, 129.

[2] Chimenov Y., Kerppola T.K.: "Close encounters of many kinds Fos-Jun interactions that mediate transcription regulatory specifity". Oncogene, 2001, 6, 533.

[3] Shaulian E., Karin M.: "AP-I as a regulator of cell life and death". Nature Cell Biol., 2002, 4, E131.

[4] Shaulian E., Karin M.: "AP-I in cell proliferation and survival". Oncogene, 2001, 20, 2390.

[5] Miller D.A., Curran T., Verma I.M.: "c-Fos protein can induce eellular transformation: a novel mechanism of a cellular oncogene". Cell, 1984, 36, 51.

[6] Maki Y，Bos T., Davis C., Starbuck M., Vogt P.: "Avian sarcoma virus 17 carries the jun oncogene". Proc. Natl. Acad. Sci. USA, 1987, 84, 2848.

[7] Ransone L.J., Verma I.M.: "Nuclear proto-oncogenes fos and jun". Ann. Rev. Cell Biol., 1990, 6, 539.

[8] Vogt P.K.: "Fortuitous convergences: the beginnings of JUN". Nature Rev. Cancer, 2002, 2, 465.

[9] Eferl R., Wagner E.F.: "AP- I: a double edged sword in tumorigenesis". Nature Rev. Cancer, 2003, 3, 859.

[10] Van Dam H., Castellazzi M.: "Distinct roles of Jun: Fos and Jun: ATF dimers in oncogenesis". Oncogene, 2001, 20, 2453.

[11] Smith L.M., Wise S.C., Hendricks D.T., Sabichi A.L., Bos T., Reddy P. et al.: "c-Jun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype". Oncogene, 1999, 18, 6063.

[12] Liu Y., Ludes-Meyers J., ZhangY., Munoz-Medellin D., Kim H.T., Lu C. et al.: "Inhibition of AP-I transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth". Oncogene, 2002, 21, 7680.

[13] Marconcini L. et al.: "c-Fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro". Proc. Natl. Acad. USA, 1999, 96, 9671.

[14] Chang L., Karin M.: "Mammalian MAP kinase signalling cascades". Nature, 2001, 410, 37.

[15] Schutte J., Viallet J., Nau M., Segal S., Fedorko J., Minna J.: "JunB inhibits and cFos stimulates the transforming and transactivating activities of cJun". Cell, 1989, 59, 987.

[16] Passegue E., Jochum W., Behrens A., Ricci R., Wagner E.F.: "JunB can substitute for Jun in mouse development and cell proliferation". Nat. Gent., 2002, 30, 158.

[17] Castellazzi M., Spyrou G., La Vista N., Dangy J.P., Piu F., Yaniv M., Brun G.: "Overexpression of cjun, junB and junD affects cell growth differentially". Proc. Natl. Acad. Sci. USA, 1991, 88, 8890.

[18] Agarwal S.K, Novotny E.A., Crabtree J.S., Weitzman J.B., Yaniv M., Burns A.L. et al.: "Menin interacts with the AP! transcription factor JunD and represses JunD activated transcription". Cell, 1999, 96, 143.

[19] Weitzmann, J.B., Flette, L., Matsuo, K., Yaniv, M.: "JunD protects cells from p53 dependent senescence and apoptosis". Mot. Cell, 2000, 6, 1109.

[20] Schreiber M., Kolbus A., Piu F., Szabowski A., Mohle-Steinlein U., Tian J. et al.: "Control of cell cycle progression progression by c-jun is p53 dependent". Genes Dev., 1999, 13, 607.

[21] Remmele W., Schicktanz K.H.: "Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS)". Pathol. Res. Pract., 1993, 189, 862.

[22] Ludes-Meyers J., Zhang Y., Munoz-Medellin D., Kim H.T., Lu C., Ge G. et al.: "AP-1 blockade inhibits the growth of normal and malignant breast cells". Oncogene, 2001, 20, 2771.

[23] Liu Y., Ludes-Meyers J., Zhang Y., Munoz-Medellin D., Kim H.T., Lu C. et al.: "Inhibition of AP-I transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth". Oncogene, 2002, 21, 7680.

[24] Smith L.M., Birrer M.J., Stampfer M.R., Brown P.H.: "Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells". Cancer Res., 1997, 57, 3046.

[25] Tiniakos D.G., Scott L.E., Corbett LP., Piggott N.H., Home C.H.: "Studies of c-jun oncogene expression in human breast using a new monoclonal antibody, NCL-DK4". J. Pathol., 1994, 172, 19.

[26] Linardopoulos S., Malliri A., Pintzas A., Vassilaros S., Tsikkinis A., Spandidos D.A.: "Elevated expression of AP-I activity in human breast tumors as compared to normal adjacent tissue". Anticancer Res., 1990, 10, 1711.

[27] Szabo E., Riffe M.E., Steinberg S.M., Birrer M.J., Linnoila R.I.: "Altered cJUN Expression: An early event in human lung carcinogenesis". Cancer Res., 1996, 56, 305.

[28] Passegue E., Wagner E.F.: "JunB represses cell proliferation by transcriptional activation of p16(1NK4a) expression". EMBO J., 2000, 19, 2969.

[29] Bakiri L., Lallemand D., Bossy-Wetzel E., Yaniv M.: "Cell-cycle dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclinD expression". EMBO J., 2000, 19, 5056.

[30] Toft D.J., Rosenberg S.B., Bergers G., Volpert 0., Linzer D.I.: "Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression". Proc. Natl. Acad. Sci. USA, 2001, 98, 13055.

[31] Yoshioka K., Deng T., Cavigelli M., Karin M.: "Antitumor promotion by phenolic antioxidants: Inhibition of AP-I activity through induction of Fral expression". Proc. Natl. Acad. Sci. USA, 1995, 92, 4972.

[32] Philips A., Teyssier C., Galtier F., Rivier-Covas C., Rey J.M., Rochefort H., Chalbos D.: "Fral Expression level modulates regulation of activator protein-I activity by estradiol in breast cancer cells". Mol. Endokrinol., 1998, 12, 973.

[33] Mechta F., Lallemand D., Pfarr C.M., Yaniv M.: "Transformation by ras modifies APl composition and activity". Oncogene, 1997, 14, 837.

[34] Kustikova 0., Kramerov D., Grigorian M., Berezin V., Bock E., Lukanidin E., Tulchinsky E.: "Fral induces morphological transformation and increases in vitro invasiveness and motility of epitheloid adenocarcinoma cells". Mol. Cell. Biol., 1998, 18, 7095.

[35] Bamberger A.-M. Methner C., Lisboa B.W., Stadtler C., Schulte H.M., Loning T., Milde-Langosch K.: "Expression pattern of the AP-I family in breast cancer: association of FosB expression with a well-differentiated, receptor-positive phenotype". Int. J. Cancer, 1999, 84, 533.

[36] Hennigan R.F., Hawker K.L., Ozanne B.W.: "Fos-transformation activates genes associated with invasion". Oncogene, 1994, 9, 3591.

[37] Smith L.M., Wise S.C., Hendricks D.T., Sabichi A.L., Bos T., Reddy P., Brown P.H., Birrer M.J.: "cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype". Oncogene, 1999, 18, 6063.